ClinicalTrials.gg
CompletedNCT04946305Updated Aug 9, 2024

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

An observational study in Somatostatin Receptor-positive GEP-NET, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
89
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

02

Conditions studied

  • Somatostatin Receptor-positive GEP-NET

Keywords

  • somatostatin receptor-positive GEP-NET
  • Lutathera
  • Observational
  • prospective
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.

    - somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.

  2. Patients who are willing to provide written .

Exclusion criteria

Exclusion Criteria:

1. Patients with according to prescribing information for Lutathera in Korea.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
89 participants (actual)
Patient registry
No

Groups and cohorts

  • Lutathera

    Patients administered Lutathera by prescription

    Other: Lutathera

Interventions

  • OtherLutathera

    Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Incidence of Adverse Events (AEs), Serious AE and unexpected AEs.

    Time frame: Up to 36 weeks

  2. Incidence of Adverse Drug Reactions

    Incidence of Adverse Drug Reactions (ADRs), Serious ADRs and unexpected ADRs.

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Effectiveness in terms of Overall Response Rate (ORR)

    ORR is defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1. Partial Response (PR): At least a 30% decrease from baseline, confirmed at 4 weeks. Complete Response (CR): Disappearance of all known disease, confirmed at 4 weeks, lymph nodes must be less than 10 mm short axis

    Time frame: Up to 32 weeks (4 cycles of 8 weeks)

07

Study locations

6 sites
  • Novartis Investigative Site
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Seoul, 110-799, South Korea
  • Novartis Investigative Site
    Seoul, 137-040, South Korea
  • Novartis Investigative Site
    Seoul, 138-736, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jul 2024, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Jun 30, 2021
StartActual
May 10, 2022
Primary completionActual
Jul 8, 2024
CompletionActual
Jul 8, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04946305
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
May 10, 2022
Primary completion
Jul 8, 2024
Completion
Jul 8, 2024
Last update
Aug 9, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion